616.234.5000

Jinyan Feng, Ph.D.

Jinyan Feng, Ph.D.
Postdoctoral fellow, Shi Laboratory
616.234.5840

Biography

Dr. Jinyan Feng earned her B.S. in biotechnology from Henan University of Urban Construction and her Ph.D. in biochemistry and molecular biology from Nankai University. Her graduate work focused on the modulation of HBV life cycle, as well as the effects of aspirin on cancer cells. Her laboratory skills include bioinformatics analysis, and molecular and cellular biology research. In 2018, she joined the laboratory of Dr. Xiaobing Shi at Van Andel Research Institute as a postdoctoral fellow.

 

Current research focus

Recognition of histones by readers is a fundamental mechanism for the regulation of chromatin and transcription. Most reader modules target specific post-translational modifications on histones. Our findings suggest that the histone binding function of ZZ domains and BIR domains of some proteins are essential in chromatin targeting and the downstream gene transcription. In the present study, we are investigating the specific function of ZZ domains of p62 and ZZEF1, as well as the BIR domain of cIAP2 in histone binding, gene transcription and other cellular processes.

Education & Training

Ph.D. in biochemistry and molecular biology, Nankai University, Institute for Molecular Biology (Advisor: Xiaodong Zhang)
Thesis: Investigating the mechanism by which pseudogenes modulate Hepatitis B Virus cccDNA formation through regulating its ancestral PCNA in hepatocarcinogenesis.

B.S. in biotechnology, Henan University of Urban Construction

Awards & External Funding

The Merit Student of Nankai University, Tianjin, China (2018)

National Scholarship of China (2017–2018)

The Master Class Scholarship of Nankai University, Tianjin, China (2013–2018)

The Merit Student of Henan province, Henan, China (2012–2013)

National Scholarship of China (2011–2012)

National Encouragement Scholarship (2010–2011)

Scholarship for Outstanding Students (2009–2010)

Publications

To view a list of selected publications click below.

Read More

Liu YX*, Feng JY*, Sun MM, Liu BW, Yang G, Bu YN, Zhao M, Wang TJ, Zhang WY, Yuan HF, Zhang XD. 2018. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta Pharmacologica Sinica.
*Co-first author

Gao Y, Feng J, Yang G, Zhang S, Liu Y, Bu Y, Sun M, Zhao M, Chen F, Zhang W, Ye L, Zhang X. 2017. HBx-elevated MSL2 modulates HBV cccDNA through inducing degradation of APOBEC3B to enhance hepatocarcinogenesis. Hepatology 66(5):1413–1429.
*Co-first author

Yang G, Wang Y, Feng J, Liu Y, Wang T, Zhao M, Ye L, Zhang X. 2017. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NF-κB/ACSL1 signaling. Biochem  Biophys Res Commun 486(3):827–832.

Wang Y, Chen F, Yang Z, Zhao M, Zhang S, Gao Y, Feng J, Yang G, Zhang W, Ye L, Zhang X. 2017. The fragment HMGA2-sh-3p20 from HMGA2 mRNA 3’UTR promotes the growth of hepatoma cells by upregulating HMGA2. Sci Rep 7:2070.